Prostate Radiotherapy
Hormone Therapy With Prostate Radiation: Who Needs It and for How Long?
A 2026 guideline and patient-level meta-analysis clarify how prostate cancer risk influences androgen-deprivation therapy with radiation.
Short answer: Androgen-deprivation therapy (ADT) improves the value of radiation for many people with unfavorable intermediate- or high-risk prostate cancer. It is not automatically needed for low-risk disease. The recommended duration ranges from months to years because benefit and harm change with risk.
What does ADT add?
Prostate cancer often depends on androgen signaling. ADT lowers that signaling and can:
- reduce cancer volume before radiation;
- make cancer cells more sensitive to treatment; and
- lower recurrence and metastasis risk in appropriate groups.
ADT does not replace radiation when definitive local treatment is recommended.
What does the 2026 guideline say?
The AUA/ASTRO guideline recommends offering radiation plus ADT as an alternative to surgery for unfavorable intermediate- and high-risk localized disease in people with sufficient life expectancy.
For high-risk cancer treated with radiation, it recommends 18 to 36 months of ADT. Favorable intermediate-risk disease may often be treated without ADT, while unfavorable intermediate-risk disease commonly receives a shorter course.
Risk grouping depends on PSA, Grade Group, stage, number of adverse features, imaging, and sometimes genomic information.
What did the large meta-analysis add?
A patient-level analysis combined 13 randomized phase 3 trials and 10,266 participants, with a median follow-up of 11.3 years. Longer ADT reduced distant metastasis and prostate-cancer death, but estimated relative benefits diminished beyond roughly 9 to 12 months for several endpoints.
The analysis also found a near-linear increase in other-cause mortality with longer exposure. It did not overturn high-risk guideline recommendations. Instead, it provides better estimates for individualized discussion.
What are the tradeoffs?
Possible effects include hot flashes, fatigue, sexual dysfunction, loss of muscle and bone density, weight and metabolic changes, mood or cognitive symptoms, and cardiovascular concerns. Risk varies by drug, duration, age, and baseline health.
Before treatment, ask about exercise, bone health, cardiovascular risk, diabetes monitoring, and symptom management.
Questions for your care team
Ask which risk feature drives the recommendation, what absolute benefit ADT is expected to add, why a specific duration was chosen, and how other health conditions change the balance. The right course is long enough to preserve proven cancer benefit without extending treatment simply because “more” sounds safer.
Questions patients often ask
Does everyone receiving prostate radiation need hormone therapy?
No. Need and duration depend on risk group, life expectancy, radiation approach, and other health factors.
Why is ADT combined with radiation?
ADT lowers androgen signaling, which can slow prostate cancer and improve the effectiveness of radiation in selected risk groups.
Can ADT duration be shortened?
Sometimes, but the decision must balance cancer risk against metabolic, cardiovascular, bone, sexual, and quality-of-life effects. High-risk guidance still recommends long-course treatment.
Sources and further reading
- Clinically Localized Prostate Cancer: AUA/ASTRO Guideline. American Urological Association (2026).
- Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy. JAMA Oncology (2026).
- ADT Practice Patterns in High-Risk Prostate Cancer Treated With Definitive Radiotherapy. Journal of Clinical Oncology (2025).
